SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Alhemo

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US (FDA approved December 2024, label expanded July 2025) and EU (EMA approved December 2024, expanded July 2025).
Why 3/10
Alhemo is already approved and commercially launched in both the US (FDA approved December 2024 for inhibitor patients, expanded July 2025 for non-inhibitor patients) and EU (EMA approved December 2024, expanded July 2025). The pediatric extension application was withdrawn in September 2026. No hard binary catalyst (PDUFA, pivotal readout) is scheduled in the next 12 months. As an approved, marketed drug at a company dominated by GLP-1 therapies, Alhemo is a small part of Novo Nordisk's value.
Actionable Insight NEUTRAL

Alhemo is already approved and launching commercially in both the US and EU. The next meaningful event would be quarterly sales disclosures from Novo Nordisk, but as a small part of a GLP-1-dominated portfolio, Alhemo-specific revenue is unlikely to move NVO shares. Watch for any future pediatric label expansion efforts or new clinical data at hematology congresses.

Price Chart

Loading chart...

Executive Summary

Alhemo (concizumab) is a once-daily subcutaneous monoclonal antibody from Novo Nordisk approved for routine prophylaxis to prevent bleeding episodes in adults and children 12+ with hemophilia A or B, with or without inhibitors. The FDA initially approved it in December 2024 for inhibitor patients and expanded the label in July 2025 to include patients without inhibitors; EMA approvals followed a similar timeline. A pediatric extension to children under 12 was withdrawn in Europe in September 2026. Alhemo competes in a crowded hemophilia market against Roche's Hemlibra, Sanofi's Qfitlia, and Pfizer's Hympavzi. For Novo Nordisk (NVO), a $300B+ market cap company driven primarily by GLP-1 drugs, Alhemo is a small rare-disease asset with projected peak sales of $1-2B by 2030, making it a minor contributor to the overall investment thesis.

How It Works

Alhemo is a monoclonal antibody that blocks tissue factor pathway inhibitor (TFPI), a natural protein that slows down blood clotting. By blocking TFPI, Alhemo helps restore the blood's ability to clot, reducing the frequency of bleeding episodes in people with hemophilia A or B. It is given as a once-daily injection under the skin using a prefilled pen.

Trial Status

Alhemo's approval was supported by the Phase 3 explorer7 trial (hemophilia with inhibitors) and explorer8 trial (hemophilia without inhibitors). Longer-term follow-up data from explorer7 showed sustained efficacy and consistent safety. First-time results from the Phase 3 explorer10 trial in children under 12 with inhibitors were presented at ISTH 2026 (July 2026), showing an 82% reduction in annualized bleeding rate, though the EMA pediatric extension application was withdrawn in September 2026.

The Two-Sided Case

▲ Bull Case5
Alhemo is the first once-daily subcutaneous prophylaxis approved for hemophilia A and B both with and without inhibitors, offering a convenient alternative to intravenous factor replacement.
Phase 3 explorer7 and explorer8 trials demonstrated significant reductions in annualized bleeding rates, and explorer10 data (ISTH July 2026) showed an 82% bleed reduction in children under 12 with inhibitors.
The global hemophilia market is estimated at ~$15-17 billion in 2026 and growing at 5-7% CAGR, providing a large addressable market for a novel non-factor therapy.
Analyst projections suggest Alhemo could reach $1-2 billion in annual sales by 2030, contributing incremental growth to Novo Nordisk's rare disease franchise.
Several tracked institutional investors added or initiated positions in NVO in Q2/Q3 2026, including Goldman Sachs (add, +79%), BlackRock (add, +31%), and Fred Alger (new position).
▼ Bear Case5
Alhemo faces entrenched competition from Roche's Hemlibra (emicizumab), Sanofi's newly approved Qfitlia (fitusiran), and Pfizer's Hympavzi (marstacimab), all targeting similar hemophilia populations.
Novo Nordisk withdrew its EMA application to extend Alhemo to children under 12 in September 2026, citing partial data from an ongoing study, capping the addressable pediatric market.
As a once-daily subcutaneous injection, Alhemo may face adherence and convenience challenges versus less frequent dosing options like monthly fitusiran.
Alhemo is a very small part of Novo Nordisk's overall business, which is dominated by GLP-1 diabetes and obesity drugs; even strong Alhemo sales would have negligible impact on NVO's share price.
Novo Nordisk's stock has fallen significantly from its 52-week high of $64.16 to $40.30, and Morgan Stanley downgraded the stock to Underweight in September 2026.

Upcoming Catalysts

  • Quarterly sales disclosures from Novo Nordisk (next: Q4 2026 earnings, expected late January/early February 2027)
  • Potential future resubmission of pediatric label extension if additional clinical data is generated
  • Real-world evidence and long-term follow-up data from ongoing extension studies

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 prnewswire.com3 fda.gov4 ema.europa.eu5 prnewswire.com6 nejm.org7 novonordisk-us.com8 docwirenews.com9 drugs.com10 ema.europa.eu11 spherixglobalinsights.com